SUBSCRIBE
SUBSCRIBE

AbbVie

AbbVie’s mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women’s health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook, Instagram, and YouTube.

We are AbbVie. A global Fortune 500 biopharmaceutical company creating life-changing medicines and first-in-kind solutions that make a real difference in people’s lives.

Our 50,000+ employees across geographies, disciplines, and therapeutic areas put impact at the core of every decision. With over $50B invested in R&D since our founding in 2013, we’re always focused on helping people and communities thrive for generations to come.

  • 2025 BPTW Badge - RBG.png
  • 2024 Best Places to Work
  • 2023 Best Places to Work
  • 2022 Best Places to Work
1 North Waukegan Road
North Chicago, IL 60064
Tel: 1-800-255-5162
Visit website
Email Us
Stock Symbol: ABBV
Stock Exchange: NYSE
  • Featured Employer
NEWS
Drug Development
AbbVie’s Rinvoq Hits the Mark in Pivotal Phase III Dermatitis Trial
AbbVie announced that its Rinvoq (upadacitinib) as a monotherapy hit both primary and all secondary endpoints in the second Phase III trial, Measure Up 2, in patients with moderate to severe atopic dermatitis.
July 22, 2020
 · 
2 min read
 · 
Mark Terry
Abicipar pegol rejected by FDA
FDA
Allergan/AbbVie’s Macular Degeneration Drug Abicipar Pegol Rejected by FDA
The U.S. Food and Drug Administration issued a Complete Response Letter, a rejection, of Allergan’s Biologics License Application for Abicipar pegol for neovascular age-related macular degeneration.
June 26, 2020
 · 
3 min read
 · 
Mark Terry
Business
Sosei Heptares and AbbVie Partner on Inflammatory and Autoimmune Diseases
The companies will work to discover, develop and commercialize novel therapies that modulate G protein-coupled receptor (GPCR) targets that AbbVie selects.
June 25, 2020
 · 
3 min read
 · 
Mark Terry
BioMidwest
AbbVie and Alpine Immune Ink $865 Million Deal to License Drug for Lupus and Other Inflammatory Diseases
Under the terms of the deal, AbbVie is paying Alpine an upfront payment of $60 million for rights to ALPN-101, a first-in-class dual CD28/ICOS costimulation antagonist.
June 18, 2020
 · 
3 min read
 · 
Mark Terry
BioMidwest
AbbVie’s Venclexta and Chemo Combination Decreases Death by 34% in AML
AbbVie reported positive results from the VIALE-A clinical trial of Venclexta plus azacytidine in previously untreated acute myeloid leukemia (AML) patients who were ineligible for intensive chemotherapy.
June 15, 2020
 · 
2 min read
 · 
Mark Terry
Business
AbbVie Plunks Down $750 Million Upfront for Cancer Therapy Deal with Genmab
The collaboration will focus on the development of three of Genmab’s bispecific antibodies and will also involve a discovery research collaboration for future antibody therapeutics for cancer.
June 10, 2020
 · 
3 min read
 · 
Alex Keown
BioForest
Clinical Catch-Up: May 31-June 5
As summer begins, we’re seeing a shift away from COVID-19-related news and a stronger output of other clinical trial news. Here’s a look.
June 5, 2020
 · 
10 min read
 · 
Mark Terry
Policy
Biopharma Update on the Novel Coronavirus: June 5
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 5, 2020.
June 5, 2020
 · 
3 min read
 · 
BioSpace Editorial Staff
Oriahnn is the new non-surgical treatment for heav
FDA
FDA Approves New Treatment Oriahnn for Heavy Menstrual Bleeding Associated with Uterine Fibroids
AbbVie won first-of-its-kind approval for a non-surgical treatment, Oriahnn, aimed at treating heavy menstrual bleeding due to uterine fibroids, a common non-cancerous tumor, in pre-menopausal women.
June 1, 2020
 · 
2 min read
 · 
Alex Keown
Load More
JOBS
View All Jobs at AbbVie
IN THE PRESS
BioMidwest
AbbVie Highlights Innovative Research From Its Rheumatology Portfolio at ACR Convergence 2021
November 1, 2021
 · 
27 min read
BioMidwest
U.S. Food and Drug Administration Approves VUITY™ (pilocarpine HCI ophthalmic solution) 1.25%, the First and Only Eye Drop to Treat Presbyopia (Age-Related Blurry Near Vision)
October 29, 2021
 · 
7 min read
Drug Development
AbbVie’s Cariprazine (VRAYLAR®) Met Primary Endpoint in Phase 3 Study as an Adjunctive Treatment for Major Depressive Disorder
October 29, 2021
 · 
14 min read
Business
AbbVie Reports Third-Quarter 2021 Financial Results
October 29, 2021
 · 
27 min read
Drug Development
AbbVie Announces ABBV-951 (Foslevodopa/Foscarbidopa) Showed Improvement in Controlling Motor Fluctuations Compared to Oral Levodopa/Carbidopa Medication in Pivotal Phase 3 Trial in Patients with Advanced Parkinson’s Disease
October 28, 2021
 · 
9 min read
BioMidwest
AbbVie Receives CHMP Positive Opinion for Risankizumab (SKYRIZI®) for the Treatment of Adults with Active Psoriatic Arthritis in the European Union (EU)
October 15, 2021
 · 
10 min read
Drug Development
AbbVie’s Upadacitinib (RINVOQ®) Met Primary and Most Ranked Secondary Endpoints in Phase 3 Study for Non-Radiographic Axial Spondyloarthritis
October 7, 2021
 · 
17 min read
Drug Development
AbbVie’s RINVOQ® (upadacitinib) Met Primary and All Ranked Secondary Endpoints in Phase 3 Study in Ankylosing Spondylitis
October 7, 2021
 · 
17 min read
Business
AbbVie to Host Third-Quarter 2021 Earnings Conference Call
October 5, 2021
 · 
1 min read
BioMidwest
AbbVie to Showcase New Data at the United European Gastroenterology (UEG) Week Virtual 2021
October 2, 2021
 · 
24 min read
Load More